In October 2020, the ‘Procedura semplificata di prezzo e rimborso per i farmaci equivalenti/biosimilari (generici)’ [Simplified price and...
Watch our webinar replay : AMNOG impact on European countries?! Dr. Stefan Walzer discussed this issue together with country experts across Europe.
Join our webinar : What does the Brexit effect mean for UK patient access? on march 29 2022.
From 1st February 2022, the National Institute for Health and Care Excellence (NICE) will introduce changes that aim to simplify and speed up Health Technology Assessments (HTA).
The new Italian Law on Rare disease : access to orphan drugs, support for research, solidarity fund.
On 27 November 2021, Law No. 175/2021, was published in the Official Journal. This is the first law dedicated exclusively to rare diseases. It’s main objective is the protection of the right to health of those suffering from rare diseases.
In 2013, a procedure was set up by the Spanish Medicines Agency to prepare the so-called Therapeutic Positioning Reports (Informes de Posicionamiento Terapéutico, IPT).
NICE (National Institute for Health and Care Excellence) uses the incremental cost effectiveness ratio (ICER) to make decision about the approval of a new product.
Join our webinar : AMNOG impact on European countries?! on the december 16 2021. Dr. Stefan Walzer will discuss this issue together with country experts across Europe.
Health policy experts are currently racing against time to finalise their contributions to one of the most important EU health care reforms in decades, the revision of the general pharmaceutical legislation
The Covid-19 pandemic hit the Italian economy harder than other European countries. The country was hit first and the hardest by the health crisis.
On 15 September, European Commission President Ursula Von Der Leyen gave her annual State of the Union address to the European Parliament.
Discover the first “Atlas of social inequalities in the use of drugs for the treatment of the main #chronic diseases” presented by the Italian Medicines Agency.